What are you looking for?

Need help finding what you are looking for? Contact Us

Compare

Free Samples

Home Market Research Reports Pharmaceutical

PUBLISHER: 360iResearch | PRODUCT CODE: 1497615

PUBLISHER: 360iResearch | PRODUCT CODE: 1497615

Alport Syndrome Market by Product (Diagnosis, Treatments), Genetic Type (Autosomal Dominant Alport Syndrome, Autosomal Recessive Alport Syndrome, X-linked Alport Syndrome), End-Use - Global Forecast 2024-2030

PUBLISHED: June 5, 2024

PAGES: 185 Pages

DELIVERY TIME: 1-2 business days

ADD TO COMPARE

SELECT AN OPTION

List of Tables

[185 Pages Report] The Alport Syndrome Market size was estimated at USD 1.59 billion in 2023 and expected to reach USD 1.77 billion in 2024, at a CAGR 11.54% to reach USD 3.43 billion by 2030.

Alport syndrome is a genetic condition indicated by hearing loss, kidney disease, and eye abnormalities. It is caused by mutations in the genes responsible for producing collagen in the kidneys, eyes, and inner ears, which leads to progressive loss of kidney function as well as sensory deficits. Increase in genetic research and understanding of Alport Syndrome mechanisms for advancements in genetic testing and diagnostic solutions driving the market growth. Moreover, increasing prevalence of genetic disorders across the globe owing to the market expansion. However, the Alport syndrome market faces several limitations, such as the complexity of the genetic basis of the disease, which makes drug development difficult. The small patient population limits the potential for large-scale clinical trials, and diverse genetic mutations require bespoke treatment approaches, increasing development costs and complexity. Furthermore, recent advancements in gene therapy and stem cell research offer potential opportunities for the development of new treatments for Alport Syndrome. Additionally, growing investment in rare disease research also presents opportunities for market expansion.

KEY MARKET STATISTICS
Base Year [2023]	USD 1.59 billion
Estimated Year [2024]	USD 1.77 billion
Forecast Year [2030]	USD 3.43 billion
CAGR (%)	11.54%

Regional Insights

The American region represents a significant market for Alport Syndrome treatments due to its advanced healthcare system and higher awareness about genetic disorders. Consumers across the region show a preference for newer treatment options that promise better efficacy and fewer side effects. There is a substantial level of investment in genetic research to support the research initiatives by governments and the private sector. European Union countries demonstrate distinct healthcare systems and variable access to treatments for rare diseases, including Alport Syndrome. EU legislation encourages the development of treatments for rare diseases, which has led to increased investment and research. European consumers benefit from facilitating access to diagnosis and treatment for rare diseases across member states. In the Middle East, countries such as Saudi Arabia have invested heavily in healthcare infrastructure and offer specialized services for rare disorders, suggesting a growing market for treatments. APAC region's massive population and improving healthcare system suggest potential growth for the Alport Syndrome treatment market. The government's increasing support for healthcare and focus on tackling rare diseases. Additionally, APAC countries' growing pharmaceutical sector actively seeks patents on new treatments, investing in both research and development.

Market Insights

Market Dynamics

The market dynamics represent an ever-changing landscape of the Alport Syndrome Market by providing actionable insights into factors, including supply and demand levels. Accounting for these factors helps design strategies, make investments, and formulate developments to capitalize on future opportunities. In addition, these factors assist in avoiding potential pitfalls related to political, geographical, technical, social, and economic conditions, highlighting consumer behaviors and influencing manufacturing costs and purchasing decisions.

Market Drivers
- Increasing prevalence of genetic disorders across the globe
- Ongoing advancements in genetic diagnostic solutions for Alport syndrome
- Emerging new treatments and therapies in clinical trials

Market Restraints
- High costs associated with surgeries and treatment processes for Alport syndrome

Market Opportunities
- Increase in the number of research and development activities
- Growing investment in rare disease research from public & private sectors

Market Challenges
- Complexities associate of the genetic based drug developments

Market Segmentation Analysis
- Product: Rising research and development for innovations in early diagnosis solutions of Alport Syndrome
- Genetic Type: Ongoing therapeutic advancements in X-linked Alport Syndrome due to its rising prevalence
- End-Use: Expansion in hospitals & clinics activities to provide extensive range treatment and disease management

Market Disruption Analysis
Porter's Five Forces Analysis
Value Chain & Critical Path Analysis
Pricing Analysis
Technology Analysis
Patent Analysis
Trade Analysis
Regulatory Framework Analysis

FPNV Positioning Matrix

The FPNV positioning matrix is essential in evaluating the market positioning of the vendors in the Alport Syndrome Market. This matrix offers a comprehensive assessment of vendors, examining critical metrics related to business strategy and product satisfaction. This in-depth assessment empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success, namely Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The market share analysis is a comprehensive tool that provides an insightful and in-depth assessment of the current state of vendors in the Alport Syndrome Market. By meticulously comparing and analyzing vendor contributions, companies are offered a greater understanding of their performance and the challenges they face when competing for market share. These contributions include overall revenue, customer base, and other vital metrics. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With these illustrative details, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Recent Developments

Calliditas Therapeutics granted orphan drug designation by the FDA for the treatment of Alport syndrome with setanaxib

Calliditas Therapeutics AB has recently acquired an orphan drug designation from the US FDA for setanaxib, which is specifically aimed at treating Alport syndrome. This disorder, caused by mutations affecting collagen type 4 production, afflicts up to 60,000 individuals in the US and is recognized for triggering chronic renal conditions, ultimately progressing to end-stage renal disease. [Published On: 2023-09-27]

Eloxx Pharmaceuticals Intends to Advance ELX-02 into Pivotal Trial for the Treatment of Alport Syndrome with Nonsense Mutations Following Achievement of Remission in Patient in Phase 2 Study

Eloxx Pharmaceuticals, Inc. has made a significant stride in treating Alport syndrome, marked by promising outcomes in a Phase 2 clinical study of their investigational drug ELX-02. This novel therapy, targeting nonsense mutations, has demonstrated considerable potential given the rarity of spontaneous proteinuria reductions in such patients. [Published On: 2023-05-24]

Strategy Analysis & Recommendation

The strategic analysis is essential for organizations seeking a solid foothold in the global marketplace. Companies are better positioned to make informed decisions that align with their long-term aspirations by thoroughly evaluating their current standing in the Alport Syndrome Market. This critical assessment involves a thorough analysis of the organization's resources, capabilities, and overall performance to identify its core strengths and areas for improvement.

Key Company Profiles

The report delves into recent significant developments in the Alport Syndrome Market, highlighting leading vendors and their innovative profiles. These include AstraZeneca PLC, Boehringer Ingelheim International GmbH, Calliditas Therapeutics AB, CENTOGENE N.V., Chinook Therapeutics Inc., Daiichi Sankyo Company, Limited, Eloxx Pharmaceuticals, Inc., Eurofins Scientific SE, GlaxoSmithKline PLC, Illumina Inc, Invitae Corp., Merck & Co., Inc., Mylan N.V., Natera, Inc., Oxalo Therapeutics, Pfizer Inc., Quest Diagnostics Incorporated, Reata Pharmaceuticals, Inc. by Biogen Inc., Sanofi S.A., Teva Pharmaceutical Industries Ltd., and Travere Therapeutics, Inc..

Market Segmentation & Coverage

This research report categorizes the Alport Syndrome Market to forecast the revenues and analyze trends in each of the following sub-markets:

Product
- Diagnosis
  - Blood Test
  - Genetic Test
  - Kidney Biopsy

Treatments
- Medications
- Surgery

Genetic Type
- Autosomal Dominant Alport Syndrome
- Autosomal Recessive Alport Syndrome
- X-linked Alport Syndrome

End-Use
- Diagnostic Centers & Laboratories
- Hospitals & Clinics

Region
- Americas
  - Argentina
  - Brazil
  - Canada
  - Mexico
  - United States
    - California
    - Florida
    - Illinois
    - New York
    - Ohio
    - Pennsylvania
    - Texas
- Asia-Pacific
  - Australia
  - China
  - India
  - Indonesia
  - Japan
  - Malaysia
  - Philippines
  - Singapore
  - South Korea
  - Taiwan
  - Thailand
  - Vietnam

Europe, Middle East & Africa
- Denmark
- Egypt
- Finland
- France
- Germany
- Israel
- Italy
- Netherlands
- Nigeria
- Norway
- Poland
- Qatar
- Russia
- Saudi Arabia
- South Africa
- Spain
- Sweden
- Switzerland
- Turkey
- United Arab Emirates
- United Kingdom

Product Code: MRR-BB4648AFF3B1

1. Preface

1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders

2. Research Methodology

2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

5.1. Market Dynamics
- 5.1.1. Drivers
  - 5.1.1.1. Increasing prevalence of genetic disorders across the globe
  - 5.1.1.2. Ongoing advancements in genetic diagnostic solutions for Alport syndrome
  - 5.1.1.3. Emerging new treatments and therapies in clinical trials
- 5.1.2. Restraints
  - 5.1.2.1. High costs associated with surgeries and treatment processes for Alport syndrome
- 5.1.3. Opportunities
  - 5.1.3.1. Increase in the number of research and development activities
  - 5.1.3.2. Growing investment in rare disease research from public & private sectors
- 5.1.4. Challenges
  - 5.1.4.1. Complexities associate of the genetic based drug developments
5.2. Market Segmentation Analysis
- 5.2.1. Product: Rising research and development for innovations in early diagnosis solutions of Alport Syndrome
- 5.2.2. Genetic Type: Ongoing therapeutic advancements in X-linked Alport Syndrome due to its rising prevalence
- 5.2.3. End-Use: Expansion in hospitals & clinics activities to provide extensive range treatment and disease management
5.3. Market Disruption Analysis
5.4. Porter's Five Forces Analysis
- 5.4.1. Threat of New Entrants
- 5.4.2. Threat of Substitutes
- 5.4.3. Bargaining Power of Customers
- 5.4.4. Bargaining Power of Suppliers
- 5.4.5. Industry Rivalry
5.5. Value Chain & Critical Path Analysis
5.6. Pricing Analysis
5.7. Technology Analysis
5.8. Patent Analysis
5.9. Trade Analysis
5.10. Regulatory Framework Analysis

6. Alport Syndrome Market, by Product

6.1. Introduction
6.2. Diagnosis
6.3. Treatments

7. Alport Syndrome Market, by Genetic Type

7.1. Introduction
7.2. Autosomal Dominant Alport Syndrome
7.3. Autosomal Recessive Alport Syndrome
7.4. X-linked Alport Syndrome

8. Alport Syndrome Market, by End-Use

8.1. Introduction
8.2. Diagnostic Centers & Laboratories
8.3. Hospitals & Clinics

9. Americas Alport Syndrome Market

9.1. Introduction
9.2. Argentina
9.3. Brazil
9.4. Canada
9.5. Mexico
9.6. United States

10. Asia-Pacific Alport Syndrome Market

10.1. Introduction
10.2. Australia
10.3. China
10.4. India
10.5. Indonesia
10.6. Japan
10.7. Malaysia
10.8. Philippines
10.9. Singapore
10.10. South Korea
10.11. Taiwan
10.12. Thailand
10.13. Vietnam

11. Europe, Middle East & Africa Alport Syndrome Market

11.1. Introduction
11.2. Denmark
11.3. Egypt
11.4. Finland
11.5. France
11.6. Germany
11.7. Israel
11.8. Italy
11.9. Netherlands
11.10. Nigeria
11.11. Norway
11.12. Poland
11.13. Qatar
11.14. Russia
11.15. Saudi Arabia
11.16. South Africa
11.17. Spain
11.18. Sweden
11.19. Switzerland
11.20. Turkey
11.21. United Arab Emirates
11.22. United Kingdom

12. Competitive Landscape

12.1. Market Share Analysis, 2023
12.2. FPNV Positioning Matrix, 2023
12.3. Competitive Scenario Analysis
- 12.3.1. Calliditas Therapeutics granted orphan drug designation by the FDA for the treatment of Alport syndrome with setanaxib
- 12.3.2. Eloxx Pharmaceuticals Intends to Advance ELX-02 into Pivotal Trial for the Treatment of Alport Syndrome with Nonsense Mutations Following Achievement of Remission in Patient in Phase 2 Study
12.4. Strategy Analysis & Recommendation

13. Competitive Portfolio

13.1. Key Company Profiles
13.2. Key Product Portfolio

Product Code: MRR-BB4648AFF3B1

LIST OF FIGURES

FIGURE 1. ALPORT SYNDROME MARKET RESEARCH PROCESS
FIGURE 2. ALPORT SYNDROME MARKET SIZE, 2023 VS 2030
FIGURE 3. GLOBAL ALPORT SYNDROME MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. GLOBAL ALPORT SYNDROME MARKET SIZE, BY REGION, 2023 VS 2030 (%)
FIGURE 5. GLOBAL ALPORT SYNDROME MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. ALPORT SYNDROME MARKET DYNAMICS
FIGURE 7. GLOBAL ALPORT SYNDROME MARKET SIZE, BY PRODUCT, 2023 VS 2030 (%)
FIGURE 8. GLOBAL ALPORT SYNDROME MARKET SIZE, BY PRODUCT, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL ALPORT SYNDROME MARKET SIZE, BY GENETIC TYPE, 2023 VS 2030 (%)
FIGURE 10. GLOBAL ALPORT SYNDROME MARKET SIZE, BY GENETIC TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL ALPORT SYNDROME MARKET SIZE, BY END-USE, 2023 VS 2030 (%)
FIGURE 12. GLOBAL ALPORT SYNDROME MARKET SIZE, BY END-USE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 13. AMERICAS ALPORT SYNDROME MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 14. AMERICAS ALPORT SYNDROME MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 15. UNITED STATES ALPORT SYNDROME MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 16. UNITED STATES ALPORT SYNDROME MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 17. ASIA-PACIFIC ALPORT SYNDROME MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 18. ASIA-PACIFIC ALPORT SYNDROME MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 19. EUROPE, MIDDLE EAST & AFRICA ALPORT SYNDROME MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA ALPORT SYNDROME MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 21. ALPORT SYNDROME MARKET SHARE, BY KEY PLAYER, 2023
FIGURE 22. ALPORT SYNDROME MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

TABLE 1. ALPORT SYNDROME MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
TABLE 3. GLOBAL ALPORT SYNDROME MARKET SIZE, 2018-2023 (USD MILLION)
TABLE 4. GLOBAL ALPORT SYNDROME MARKET SIZE, 2024-2030 (USD MILLION)
TABLE 5. GLOBAL ALPORT SYNDROME MARKET SIZE, BY REGION, 2018-2023 (USD MILLION)
TABLE 6. GLOBAL ALPORT SYNDROME MARKET SIZE, BY REGION, 2024-2030 (USD MILLION)
TABLE 7. GLOBAL ALPORT SYNDROME MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
TABLE 8. GLOBAL ALPORT SYNDROME MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
TABLE 9. GLOBAL ALPORT SYNDROME MARKET SIZE, BY DIAGNOSIS, BY REGION, 2018-2023 (USD MILLION)
TABLE 10. GLOBAL ALPORT SYNDROME MARKET SIZE, BY DIAGNOSIS, BY REGION, 2024-2030 (USD MILLION)
TABLE 11. GLOBAL ALPORT SYNDROME MARKET SIZE, BY DIAGNOSIS, 2018-2023 (USD MILLION)
TABLE 12. GLOBAL ALPORT SYNDROME MARKET SIZE, BY DIAGNOSIS, 2024-2030 (USD MILLION)
TABLE 13. GLOBAL ALPORT SYNDROME MARKET SIZE, BY BLOOD TEST, BY REGION, 2018-2023 (USD MILLION)
TABLE 14. GLOBAL ALPORT SYNDROME MARKET SIZE, BY BLOOD TEST, BY REGION, 2024-2030 (USD MILLION)
TABLE 15. GLOBAL ALPORT SYNDROME MARKET SIZE, BY GENETIC TEST, BY REGION, 2018-2023 (USD MILLION)
TABLE 16. GLOBAL ALPORT SYNDROME MARKET SIZE, BY GENETIC TEST, BY REGION, 2024-2030 (USD MILLION)
TABLE 17. GLOBAL ALPORT SYNDROME MARKET SIZE, BY KIDNEY BIOPSY, BY REGION, 2018-2023 (USD MILLION)
TABLE 18. GLOBAL ALPORT SYNDROME MARKET SIZE, BY KIDNEY BIOPSY, BY REGION, 2024-2030 (USD MILLION)
TABLE 19. GLOBAL ALPORT SYNDROME MARKET SIZE, BY TREATMENTS, BY REGION, 2018-2023 (USD MILLION)
TABLE 20. GLOBAL ALPORT SYNDROME MARKET SIZE, BY TREATMENTS, BY REGION, 2024-2030 (USD MILLION)
TABLE 21. GLOBAL ALPORT SYNDROME MARKET SIZE, BY TREATMENTS, 2018-2023 (USD MILLION)
TABLE 22. GLOBAL ALPORT SYNDROME MARKET SIZE, BY TREATMENTS, 2024-2030 (USD MILLION)
TABLE 23. GLOBAL ALPORT SYNDROME MARKET SIZE, BY MEDICATIONS, BY REGION, 2018-2023 (USD MILLION)
TABLE 24. GLOBAL ALPORT SYNDROME MARKET SIZE, BY MEDICATIONS, BY REGION, 2024-2030 (USD MILLION)
TABLE 25. GLOBAL ALPORT SYNDROME MARKET SIZE, BY SURGERY, BY REGION, 2018-2023 (USD MILLION)
TABLE 26. GLOBAL ALPORT SYNDROME MARKET SIZE, BY SURGERY, BY REGION, 2024-2030 (USD MILLION)
TABLE 27. GLOBAL ALPORT SYNDROME MARKET SIZE, BY GENETIC TYPE, 2018-2023 (USD MILLION)
TABLE 28. GLOBAL ALPORT SYNDROME MARKET SIZE, BY GENETIC TYPE, 2024-2030 (USD MILLION)
TABLE 29. GLOBAL ALPORT SYNDROME MARKET SIZE, BY AUTOSOMAL DOMINANT ALPORT SYNDROME, BY REGION, 2018-2023 (USD MILLION)
TABLE 30. GLOBAL ALPORT SYNDROME MARKET SIZE, BY AUTOSOMAL DOMINANT ALPORT SYNDROME, BY REGION, 2024-2030 (USD MILLION)
TABLE 31. GLOBAL ALPORT SYNDROME MARKET SIZE, BY AUTOSOMAL RECESSIVE ALPORT SYNDROME, BY REGION, 2018-2023 (USD MILLION)
TABLE 32. GLOBAL ALPORT SYNDROME MARKET SIZE, BY AUTOSOMAL RECESSIVE ALPORT SYNDROME, BY REGION, 2024-2030 (USD MILLION)
TABLE 33. GLOBAL ALPORT SYNDROME MARKET SIZE, BY X-LINKED ALPORT SYNDROME, BY REGION, 2018-2023 (USD MILLION)
TABLE 34. GLOBAL ALPORT SYNDROME MARKET SIZE, BY X-LINKED ALPORT SYNDROME, BY REGION, 2024-2030 (USD MILLION)
TABLE 35. GLOBAL ALPORT SYNDROME MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
TABLE 36. GLOBAL ALPORT SYNDROME MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
TABLE 37. GLOBAL ALPORT SYNDROME MARKET SIZE, BY DIAGNOSTIC CENTERS & LABORATORIES, BY REGION, 2018-2023 (USD MILLION)
TABLE 38. GLOBAL ALPORT SYNDROME MARKET SIZE, BY DIAGNOSTIC CENTERS & LABORATORIES, BY REGION, 2024-2030 (USD MILLION)
TABLE 39. GLOBAL ALPORT SYNDROME MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2023 (USD MILLION)
TABLE 40. GLOBAL ALPORT SYNDROME MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2024-2030 (USD MILLION)
TABLE 41. AMERICAS ALPORT SYNDROME MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
TABLE 42. AMERICAS ALPORT SYNDROME MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
TABLE 43. AMERICAS ALPORT SYNDROME MARKET SIZE, BY DIAGNOSIS, 2018-2023 (USD MILLION)
TABLE 44. AMERICAS ALPORT SYNDROME MARKET SIZE, BY DIAGNOSIS, 2024-2030 (USD MILLION)
TABLE 45. AMERICAS ALPORT SYNDROME MARKET SIZE, BY TREATMENTS, 2018-2023 (USD MILLION)
TABLE 46. AMERICAS ALPORT SYNDROME MARKET SIZE, BY TREATMENTS, 2024-2030 (USD MILLION)
TABLE 47. AMERICAS ALPORT SYNDROME MARKET SIZE, BY GENETIC TYPE, 2018-2023 (USD MILLION)
TABLE 48. AMERICAS ALPORT SYNDROME MARKET SIZE, BY GENETIC TYPE, 2024-2030 (USD MILLION)
TABLE 49. AMERICAS ALPORT SYNDROME MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
TABLE 50. AMERICAS ALPORT SYNDROME MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
TABLE 51. AMERICAS ALPORT SYNDROME MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
TABLE 52. AMERICAS ALPORT SYNDROME MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
TABLE 53. ARGENTINA ALPORT SYNDROME MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
TABLE 54. ARGENTINA ALPORT SYNDROME MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
TABLE 55. ARGENTINA ALPORT SYNDROME MARKET SIZE, BY DIAGNOSIS, 2018-2023 (USD MILLION)
TABLE 56. ARGENTINA ALPORT SYNDROME MARKET SIZE, BY DIAGNOSIS, 2024-2030 (USD MILLION)
TABLE 57. ARGENTINA ALPORT SYNDROME MARKET SIZE, BY TREATMENTS, 2018-2023 (USD MILLION)
TABLE 58. ARGENTINA ALPORT SYNDROME MARKET SIZE, BY TREATMENTS, 2024-2030 (USD MILLION)
TABLE 59. ARGENTINA ALPORT SYNDROME MARKET SIZE, BY GENETIC TYPE, 2018-2023 (USD MILLION)
TABLE 60. ARGENTINA ALPORT SYNDROME MARKET SIZE, BY GENETIC TYPE, 2024-2030 (USD MILLION)
TABLE 61. ARGENTINA ALPORT SYNDROME MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
TABLE 62. ARGENTINA ALPORT SYNDROME MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
TABLE 63. BRAZIL ALPORT SYNDROME MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
TABLE 64. BRAZIL ALPORT SYNDROME MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
TABLE 65. BRAZIL ALPORT SYNDROME MARKET SIZE, BY DIAGNOSIS, 2018-2023 (USD MILLION)
TABLE 66. BRAZIL ALPORT SYNDROME MARKET SIZE, BY DIAGNOSIS, 2024-2030 (USD MILLION)
TABLE 67. BRAZIL ALPORT SYNDROME MARKET SIZE, BY TREATMENTS, 2018-2023 (USD MILLION)
TABLE 68. BRAZIL ALPORT SYNDROME MARKET SIZE, BY TREATMENTS, 2024-2030 (USD MILLION)
TABLE 69. BRAZIL ALPORT SYNDROME MARKET SIZE, BY GENETIC TYPE, 2018-2023 (USD MILLION)
TABLE 70. BRAZIL ALPORT SYNDROME MARKET SIZE, BY GENETIC TYPE, 2024-2030 (USD MILLION)
TABLE 71. BRAZIL ALPORT SYNDROME MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
TABLE 72. BRAZIL ALPORT SYNDROME MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
TABLE 73. CANADA ALPORT SYNDROME MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
TABLE 74. CANADA ALPORT SYNDROME MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
TABLE 75. CANADA ALPORT SYNDROME MARKET SIZE, BY DIAGNOSIS, 2018-2023 (USD MILLION)
TABLE 76. CANADA ALPORT SYNDROME MARKET SIZE, BY DIAGNOSIS, 2024-2030 (USD MILLION)
TABLE 77. CANADA ALPORT SYNDROME MARKET SIZE, BY TREATMENTS, 2018-2023 (USD MILLION)
TABLE 78. CANADA ALPORT SYNDROME MARKET SIZE, BY TREATMENTS, 2024-2030 (USD MILLION)
TABLE 79. CANADA ALPORT SYNDROME MARKET SIZE, BY GENETIC TYPE, 2018-2023 (USD MILLION)
TABLE 80. CANADA ALPORT SYNDROME MARKET SIZE, BY GENETIC TYPE, 2024-2030 (USD MILLION)
TABLE 81. CANADA ALPORT SYNDROME MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
TABLE 82. CANADA ALPORT SYNDROME MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
TABLE 83. MEXICO ALPORT SYNDROME MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
TABLE 84. MEXICO ALPORT SYNDROME MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
TABLE 85. MEXICO ALPORT SYNDROME MARKET SIZE, BY DIAGNOSIS, 2018-2023 (USD MILLION)
TABLE 86. MEXICO ALPORT SYNDROME MARKET SIZE, BY DIAGNOSIS, 2024-2030 (USD MILLION)
TABLE 87. MEXICO ALPORT SYNDROME MARKET SIZE, BY TREATMENTS, 2018-2023 (USD MILLION)
TABLE 88. MEXICO ALPORT SYNDROME MARKET SIZE, BY TREATMENTS, 2024-2030 (USD MILLION)
TABLE 89. MEXICO ALPORT SYNDROME MARKET SIZE, BY GENETIC TYPE, 2018-2023 (USD MILLION)
TABLE 90. MEXICO ALPORT SYNDROME MARKET SIZE, BY GENETIC TYPE, 2024-2030 (USD MILLION)
TABLE 91. MEXICO ALPORT SYNDROME MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
TABLE 92. MEXICO ALPORT SYNDROME MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
TABLE 93. UNITED STATES ALPORT SYNDROME MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
TABLE 94. UNITED STATES ALPORT SYNDROME MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
TABLE 95. UNITED STATES ALPORT SYNDROME MARKET SIZE, BY DIAGNOSIS, 2018-2023 (USD MILLION)
TABLE 96. UNITED STATES ALPORT SYNDROME MARKET SIZE, BY DIAGNOSIS, 2024-2030 (USD MILLION)
TABLE 97. UNITED STATES ALPORT SYNDROME MARKET SIZE, BY TREATMENTS, 2018-2023 (USD MILLION)
TABLE 98. UNITED STATES ALPORT SYNDROME MARKET SIZE, BY TREATMENTS, 2024-2030 (USD MILLION)
TABLE 99. UNITED STATES ALPORT SYNDROME MARKET SIZE, BY GENETIC TYPE, 2018-2023 (USD MILLION)
TABLE 100. UNITED STATES ALPORT SYNDROME MARKET SIZE, BY GENETIC TYPE, 2024-2030 (USD MILLION)
TABLE 101. UNITED STATES ALPORT SYNDROME MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
TABLE 102. UNITED STATES ALPORT SYNDROME MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
TABLE 103. UNITED STATES ALPORT SYNDROME MARKET SIZE, BY STATE, 2018-2023 (USD MILLION)
TABLE 104. UNITED STATES ALPORT SYNDROME MARKET SIZE, BY STATE, 2024-2030 (USD MILLION)
TABLE 105. ASIA-PACIFIC ALPORT SYNDROME MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
TABLE 106. ASIA-PACIFIC ALPORT SYNDROME MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
TABLE 107. ASIA-PACIFIC ALPORT SYNDROME MARKET SIZE, BY DIAGNOSIS, 2018-2023 (USD MILLION)
TABLE 108. ASIA-PACIFIC ALPORT SYNDROME MARKET SIZE, BY DIAGNOSIS, 2024-2030 (USD MILLION)
TABLE 109. ASIA-PACIFIC ALPORT SYNDROME MARKET SIZE, BY TREATMENTS, 2018-2023 (USD MILLION)
TABLE 110. ASIA-PACIFIC ALPORT SYNDROME MARKET SIZE, BY TREATMENTS, 2024-2030 (USD MILLION)
TABLE 111. ASIA-PACIFIC ALPORT SYNDROME MARKET SIZE, BY GENETIC TYPE, 2018-2023 (USD MILLION)
TABLE 112. ASIA-PACIFIC ALPORT SYNDROME MARKET SIZE, BY GENETIC TYPE, 2024-2030 (USD MILLION)
TABLE 113. ASIA-PACIFIC ALPORT SYNDROME MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
TABLE 114. ASIA-PACIFIC ALPORT SYNDROME MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
TABLE 115. ASIA-PACIFIC ALPORT SYNDROME MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
TABLE 116. ASIA-PACIFIC ALPORT SYNDROME MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
TABLE 117. AUSTRALIA ALPORT SYNDROME MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
TABLE 118. AUSTRALIA ALPORT SYNDROME MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
TABLE 119. AUSTRALIA ALPORT SYNDROME MARKET SIZE, BY DIAGNOSIS, 2018-2023 (USD MILLION)
TABLE 120. AUSTRALIA ALPORT SYNDROME MARKET SIZE, BY DIAGNOSIS, 2024-2030 (USD MILLION)
TABLE 121. AUSTRALIA ALPORT SYNDROME MARKET SIZE, BY TREATMENTS, 2018-2023 (USD MILLION)
TABLE 122. AUSTRALIA ALPORT SYNDROME MARKET SIZE, BY TREATMENTS, 2024-2030 (USD MILLION)
TABLE 123. AUSTRALIA ALPORT SYNDROME MARKET SIZE, BY GENETIC TYPE, 2018-2023 (USD MILLION)
TABLE 124. AUSTRALIA ALPORT SYNDROME MARKET SIZE, BY GENETIC TYPE, 2024-2030 (USD MILLION)
TABLE 125. AUSTRALIA ALPORT SYNDROME MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
TABLE 126. AUSTRALIA ALPORT SYNDROME MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
TABLE 127. CHINA ALPORT SYNDROME MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
TABLE 128. CHINA ALPORT SYNDROME MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
TABLE 129. CHINA ALPORT SYNDROME MARKET SIZE, BY DIAGNOSIS, 2018-2023 (USD MILLION)
TABLE 130. CHINA ALPORT SYNDROME MARKET SIZE, BY DIAGNOSIS, 2024-2030 (USD MILLION)
TABLE 131. CHINA ALPORT SYNDROME MARKET SIZE, BY TREATMENTS, 2018-2023 (USD MILLION)
TABLE 132. CHINA ALPORT SYNDROME MARKET SIZE, BY TREATMENTS, 2024-2030 (USD MILLION)
TABLE 133. CHINA ALPORT SYNDROME MARKET SIZE, BY GENETIC TYPE, 2018-2023 (USD MILLION)
TABLE 134. CHINA ALPORT SYNDROME MARKET SIZE, BY GENETIC TYPE, 2024-2030 (USD MILLION)
TABLE 135. CHINA ALPORT SYNDROME MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
TABLE 136. CHINA ALPORT SYNDROME MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
TABLE 137. INDIA ALPORT SYNDROME MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
TABLE 138. INDIA ALPORT SYNDROME MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
TABLE 139. INDIA ALPORT SYNDROME MARKET SIZE, BY DIAGNOSIS, 2018-2023 (USD MILLION)
TABLE 140. INDIA ALPORT SYNDROME MARKET SIZE, BY DIAGNOSIS, 2024-2030 (USD MILLION)
TABLE 141. INDIA ALPORT SYNDROME MARKET SIZE, BY TREATMENTS, 2018-2023 (USD MILLION)
TABLE 142. INDIA ALPORT SYNDROME MARKET SIZE, BY TREATMENTS, 2024-2030 (USD MILLION)
TABLE 143. INDIA ALPORT SYNDROME MARKET SIZE, BY GENETIC TYPE, 2018-2023 (USD MILLION)
TABLE 144. INDIA ALPORT SYNDROME MARKET SIZE, BY GENETIC TYPE, 2024-2030 (USD MILLION)
TABLE 145. INDIA ALPORT SYNDROME MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
TABLE 146. INDIA ALPORT SYNDROME MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
TABLE 147. INDONESIA ALPORT SYNDROME MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
TABLE 148. INDONESIA ALPORT SYNDROME MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
TABLE 149. INDONESIA ALPORT SYNDROME MARKET SIZE, BY DIAGNOSIS, 2018-2023 (USD MILLION)
TABLE 150. INDONESIA ALPORT SYNDROME MARKET SIZE, BY DIAGNOSIS, 2024-2030 (USD MILLION)
TABLE 151. INDONESIA ALPORT SYNDROME MARKET SIZE, BY TREATMENTS, 2018-2023 (USD MILLION)
TABLE 152. INDONESIA ALPORT SYNDROME MARKET SIZE, BY TREATMENTS, 2024-2030 (USD MILLION)
TABLE 153. INDONESIA ALPORT SYNDROME MARKET SIZE, BY GENETIC TYPE, 2018-2023 (USD MILLION)
TABLE 154. INDONESIA ALPORT SYNDROME MARKET SIZE, BY GENETIC TYPE, 2024-2030 (USD MILLION)
TABLE 155. INDONESIA ALPORT SYNDROME MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
TABLE 156. INDONESIA ALPORT SYNDROME MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
TABLE 157. JAPAN ALPORT SYNDROME MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
TABLE 158. JAPAN ALPORT SYNDROME MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
TABLE 159. JAPAN ALPORT SYNDROME MARKET SIZE, BY DIAGNOSIS, 2018-2023 (USD MILLION)
TABLE 160. JAPAN ALPORT SYNDROME MARKET SIZE, BY DIAGNOSIS, 2024-2030 (USD MILLION)
TABLE 161. JAPAN ALPORT SYNDROME MARKET SIZE, BY TREATMENTS, 2018-2023 (USD MILLION)
TABLE 162. JAPAN ALPORT SYNDROME MARKET SIZE, BY TREATMENTS, 2024-2030 (USD MILLION)
TABLE 163. JAPAN ALPORT SYNDROME MARKET SIZE, BY GENETIC TYPE, 2018-2023 (USD MILLION)
TABLE 164. JAPAN ALPORT SYNDROME MARKET SIZE, BY GENETIC TYPE, 2024-2030 (USD MILLION)
TABLE 165. JAPAN ALPORT SYNDROME MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
TABLE 166. JAPAN ALPORT SYNDROME MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
TABLE 167. MALAYSIA ALPORT SYNDROME MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
TABLE 168. MALAYSIA ALPORT SYNDROME MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
TABLE 169. MALAYSIA ALPORT SYNDROME MARKET SIZE, BY DIAGNOSIS, 2018-2023 (USD MILLION)
TABLE 170. MALAYSIA ALPORT SYNDROME MARKET SIZE, BY DIAGNOSIS, 2024-2030 (USD MILLION)
TABLE 171. MALAYSIA ALPORT SYNDROME MARKET SIZE, BY TREATMENTS, 2018-2023 (USD MILLION)
TABLE 172. MALAYSIA ALPORT SYNDROME MARKET SIZE, BY TREATMENTS, 2024-2030 (USD MILLION)
TABLE 173. MALAYSIA ALPORT SYNDROME MARKET SIZE, BY GENETIC TYPE, 2018-2023 (USD MILLION)
TABLE 174. MALAYSIA ALPORT SYNDROME MARKET SIZE, BY GENETIC TYPE, 2024-2030 (USD MILLION)
TABLE 175. MALAYSIA ALPORT SYNDROME MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
TABLE 176. MALAYSIA ALPORT SYNDROME MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
TABLE 177. PHILIPPINES ALPORT SYNDROME MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
TABLE 178. PHILIPPINES ALPORT SYNDROME MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
TABLE 179. PHILIPPINES ALPORT SYNDROME MARKET SIZE, BY DIAGNOSIS, 2018-2023 (USD MILLION)
TABLE 180. PHILIPPINES ALPORT SYNDROME MARKET SIZE, BY DIAGNOSIS, 2024-2030 (USD MILLION)
TABLE 181. PHILIPPINES ALPORT SYNDROME MARKET SIZE, BY TREATMENTS, 2018-2023 (USD MILLION)
TABLE 182. PHILIPPINES ALPORT SYNDROME MARKET SIZE, BY TREATMENTS, 2024-2030 (USD MILLION)
TABLE 183. PHILIPPINES ALPORT SYNDROME MARKET SIZE, BY GENETIC TYPE, 2018-2023 (USD MILLION)
TABLE 184. PHILIPPINES ALPORT SYNDROME MARKET SIZE, BY GENETIC TYPE, 2024-2030 (USD MILLION)
TABLE 185. PHILIPPINES ALPORT SYNDROME MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
TABLE 186. PHILIPPINES ALPORT SYNDROME MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
TABLE 187. SINGAPORE ALPORT SYNDROME MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
TABLE 188. SINGAPORE ALPORT SYNDROME MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
TABLE 189. SINGAPORE ALPORT SYNDROME MARKET SIZE, BY DIAGNOSIS, 2018-2023 (USD MILLION)
TABLE 190. SINGAPORE ALPORT SYNDROME MARKET SIZE, BY DIAGNOSIS, 2024-2030 (USD MILLION)
TABLE 191. SINGAPORE ALPORT SYNDROME MARKET SIZE, BY TREATMENTS, 2018-2023 (USD MILLION)
TABLE 192. SINGAPORE ALPORT SYNDROME MARKET SIZE, BY TREATMENTS, 2024-2030 (USD MILLION)
TABLE 193. SINGAPORE ALPORT SYNDROME MARKET SIZE, BY GENETIC TYPE, 2018-2023 (USD MILLION)
TABLE 194. SINGAPORE ALPORT SYNDROME MARKET SIZE, BY GENETIC TYPE, 2024-2030 (USD MILLION)
TABLE 195. SINGAPORE ALPORT SYNDROME MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
TABLE 196. SINGAPORE ALPORT SYNDROME MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
TABLE 197. SOUTH KOREA ALPORT SYNDROME MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
TABLE 198. SOUTH KOREA ALPORT SYNDROME MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
TABLE 199. SOUTH KOREA ALPORT SYNDROME MARKET SIZE, BY DIAGNOSIS, 2018-2023 (USD MILLION)
TABLE 200. SOUTH KOREA ALPORT SYNDROME MARKET SIZE, BY DIAGNOSIS, 2024-2030 (USD MILLION)
TABLE 201. SOUTH KOREA ALPORT SYNDROME MARKET SIZE, BY TREATMENTS, 2018-2023 (USD MILLION)
TABLE 202. SOUTH KOREA ALPORT SYNDROME MARKET SIZE, BY TREATMENTS, 2024-2030 (USD MILLION)
TABLE 203. SOUTH KOREA ALPORT SYNDROME MARKET SIZE, BY GENETIC TYPE, 2018-2023 (USD MILLION)
TABLE 204. SOUTH KOREA ALPORT SYNDROME MARKET SIZE, BY GENETIC TYPE, 2024-2030 (USD MILLION)
TABLE 205. SOUTH KOREA ALPORT SYNDROME MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
TABLE 206. SOUTH KOREA ALPORT SYNDROME MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
TABLE 207. TAIWAN ALPORT SYNDROME MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
TABLE 208. TAIWAN ALPORT SYNDROME MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
TABLE 209. TAIWAN ALPORT SYNDROME MARKET SIZE, BY DIAGNOSIS, 2018-2023 (USD MILLION)
TABLE 210. TAIWAN ALPORT SYNDROME MARKET SIZE, BY DIAGNOSIS, 2024-2030 (USD MILLION)
TABLE 211. TAIWAN ALPORT SYNDROME MARKET SIZE, BY TREATMENTS, 2018-2023 (USD MILLION)
TABLE 212. TAIWAN ALPORT SYNDROME MARKET SIZE, BY TREATMENTS, 2024-2030 (USD MILLION)
TABLE 213. TAIWAN ALPORT SYNDROME MARKET SIZE, BY GENETIC TYPE, 2018-2023 (USD MILLION)
TABLE 214. TAIWAN ALPORT SYNDROME MARKET SIZE, BY GENETIC TYPE, 2024-2030 (USD MILLION)
TABLE 215. TAIWAN ALPORT SYNDROME MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
TABLE 216. TAIWAN ALPORT SYNDROME MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
TABLE 217. THAILAND ALPORT SYNDROME MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
TABLE 218. THAILAND ALPORT SYNDROME MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
TABLE 219. THAILAND ALPORT SYNDROME MARKET SIZE, BY DIAGNOSIS, 2018-2023 (USD MILLION)
TABLE 220. THAILAND ALPORT SYNDROME MARKET SIZE, BY DIAGNOSIS, 2024-2030 (USD MILLION)
TABLE 221. THAILAND ALPORT SYNDROME MARKET SIZE, BY TREATMENTS, 2018-2023 (USD MILLION)
TABLE 222. THAILAND ALPORT SYNDROME MARKET SIZE, BY TREATMENTS, 2024-2030 (USD MILLION)
TABLE 223. THAILAND ALPORT SYNDROME MARKET SIZE, BY GENETIC TYPE, 2018-2023 (USD MILLION)
TABLE 224. THAILAND ALPORT SYNDROME MARKET SIZE, BY GENETIC TYPE, 2024-2030 (USD MILLION)
TABLE 225. THAILAND ALPORT SYNDROME MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
TABLE 226. THAILAND ALPORT SYNDROME MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
TABLE 227. VIETNAM ALPORT SYNDROME MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
TABLE 228. VIETNAM ALPORT SYNDROME MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
TABLE 229. VIETNAM ALPORT SYNDROME MARKET SIZE, BY DIAGNOSIS, 2018-2023 (USD MILLION)
TABLE 230. VIETNAM ALPORT SYNDROME MARKET SIZE, BY DIAGNOSIS, 2024-2030 (USD MILLION)
TABLE 231. VIETNAM ALPORT SYNDROME MARKET SIZE, BY TREATMENTS, 2018-2023 (USD MILLION)
TABLE 232. VIETNAM ALPORT SYNDROME MARKET SIZE, BY TREATMENTS, 2024-2030 (USD MILLION)
TABLE 233. VIETNAM ALPORT SYNDROME MARKET SIZE, BY GENETIC TYPE, 2018-2023 (USD MILLION)
TABLE 234. VIETNAM ALPORT SYNDROME MARKET SIZE, BY GENETIC TYPE, 2024-2030 (USD MILLION)
TABLE 235. VIETNAM ALPORT SYNDROME MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
TABLE 236. VIETNAM ALPORT SYNDROME MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
TABLE 237. EUROPE, MIDDLE EAST & AFRICA ALPORT SYNDROME MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
TABLE 238. EUROPE, MIDDLE EAST & AFRICA ALPORT SYNDROME MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
TABLE 239. EUROPE, MIDDLE EAST & AFRICA ALPORT SYNDROME MARKET SIZE, BY DIAGNOSIS, 2018-2023 (USD MILLION)
TABLE 240. EUROPE, MIDDLE EAST & AFRICA ALPORT SYNDROME MARKET SIZE, BY DIAGNOSIS, 2024-2030 (USD MILLION)
TABLE 241. EUROPE, MIDDLE EAST & AFRICA ALPORT SYNDROME MARKET SIZE, BY TREATMENTS, 2018-2023 (USD MILLION)
TABLE 242. EUROPE, MIDDLE EAST & AFRICA ALPORT SYNDROME MARKET SIZE, BY TREATMENTS, 2024-2030 (USD MILLION)
TABLE 243. EUROPE, MIDDLE EAST & AFRICA ALPORT SYNDROME MARKET SIZE, BY GENETIC TYPE, 2018-2023 (USD MILLION)
TABLE 244. EUROPE, MIDDLE EAST & AFRICA ALPORT SYNDROME MARKET SIZE, BY GENETIC TYPE, 2024-2030 (USD MILLION)
TABLE 245. EUROPE, MIDDLE EAST & AFRICA ALPORT SYNDROME MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
TABLE 246. EUROPE, MIDDLE EAST & AFRICA ALPORT SYNDROME MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
TABLE 247. EUROPE, MIDDLE EAST & AFRICA ALPORT SYNDROME MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
TABLE 248. EUROPE, MIDDLE EAST & AFRICA ALPORT SYNDROME MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
TABLE 249. DENMARK ALPORT SYNDROME MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
TABLE 250. DENMARK ALPORT SYNDROME MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
TABLE 251. DENMARK ALPORT SYNDROME MARKET SIZE, BY DIAGNOSIS, 2018-2023 (USD MILLION)
TABLE 252. DENMARK ALPORT SYNDROME MARKET SIZE, BY DIAGNOSIS, 2024-2030 (USD MILLION)
TABLE 253. DENMARK ALPORT SYNDROME MARKET SIZE, BY TREATMENTS, 2018-2023 (USD MILLION)
TABLE 254. DENMARK ALPORT SYNDROME MARKET SIZE, BY TREATMENTS, 2024-2030 (USD MILLION)
TABLE 255. DENMARK ALPORT SYNDROME MARKET SIZE, BY GENETIC TYPE, 2018-2023 (USD MILLION)
TABLE 256. DENMARK ALPORT SYNDROME MARKET SIZE, BY GENETIC TYPE, 2024-2030 (USD MILLION)
TABLE 257. DENMARK ALPORT SYNDROME MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
TABLE 258. DENMARK ALPORT SYNDROME MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
TABLE 259. EGYPT ALPORT SYNDROME MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
TABLE 260. EGYPT ALPORT SYNDROME MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
TABLE 261. EGYPT ALPORT SYNDROME MARKET SIZE, BY DIAGNOSIS, 2018-2023 (USD MILLION)
TABLE 262. EGYPT ALPORT SYNDROME MARKET SIZE, BY DIAGNOSIS, 2024-2030 (USD MILLION)
TABLE 263. EGYPT ALPORT SYNDROME MARKET SIZE, BY TREATMENTS, 2018-2023 (USD MILLION)
TABLE 264. EGYPT ALPORT SYNDROME MARKET SIZE, BY TREATMENTS, 2024-2030 (USD MILLION)
TABLE 265. EGYPT ALPORT SYNDROME MARKET SIZE, BY GENETIC TYPE, 2018-2023 (USD MILLION)
TABLE 266. EGYPT ALPORT SYNDROME MARKET SIZE, BY GENETIC TYPE, 2024-2030 (USD MILLION)
TABLE 267. EGYPT ALPORT SYNDROME MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
TABLE 268. EGYPT ALPORT SYNDROME MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
TABLE 269. FINLAND ALPORT SYNDROME MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
TABLE 270. FINLAND ALPORT SYNDROME MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
TABLE 271. FINLAND ALPORT SYNDROME MARKET SIZE, BY DIAGNOSIS, 2018-2023 (USD MILLION)
TABLE 272. FINLAND ALPORT SYNDROME MARKET SIZE, BY DIAGNOSIS, 2024-2030 (USD MILLION)
TABLE 273. FINLAND ALPORT SYNDROME MARKET SIZE, BY TREATMENTS, 2018-2023 (USD MILLION)
TABLE 274. FINLAND ALPORT SYNDROME MARKET SIZE, BY TREATMENTS, 2024-2030 (USD MILLION)
TABLE 275. FINLAND ALPORT SYNDROME MARKET SIZE, BY GENETIC TYPE, 2018-2023 (USD MILLION)
TABLE 276. FINLAND ALPORT SYNDROME MARKET SIZE, BY GENETIC TYPE, 2024-2030 (USD MILLION)
TABLE 277. FINLAND ALPORT SYNDROME MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
TABLE 278. FINLAND ALPORT SYNDROME MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
TABLE 279. FRANCE ALPORT SYNDROME MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
TABLE 280. FRANCE ALPORT SYNDROME MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
TABLE 281. FRANCE ALPORT SYNDROME MARKET SIZE, BY DIAGNOSIS, 2018-2023 (USD MILLION)
TABLE 282. FRANCE ALPORT SYNDROME MARKET SIZE, BY DIAGNOSIS, 2024-2030 (USD MILLION)
TABLE 283. FRANCE ALPORT SYNDROME MARKET SIZE, BY TREATMENTS, 2018-2023 (USD MILLION)
TABLE 284. FRANCE ALPORT SYNDROME MARKET SIZE, BY TREATMENTS, 2024-2030 (USD MILLION)
TABLE 285. FRANCE ALPORT SYNDROME MARKET SIZE, BY GENETIC TYPE, 2018-2023 (USD MILLION)
TABLE 286. FRANCE ALPORT SYNDROME MARKET SIZE, BY GENETIC TYPE, 2024-2030 (USD MILLION)
TABLE 287. FRANCE ALPORT SYNDROME MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
TABLE 288. FRANCE ALPORT SYNDROME MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
TABLE 289. GERMANY ALPORT SYNDROME MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
TABLE 290. GERMANY ALPORT SYNDROME MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
TABLE 291. GERMANY ALPORT SYNDROME MARKET SIZE, BY DIAGNOSIS, 2018-2023 (USD MILLION)
TABLE 292. GERMANY ALPORT SYNDROME MARKET SIZE, BY DIAGNOSIS, 2024-2030 (USD MILLION)
TABLE 293. GERMANY ALPORT SYNDROME MARKET SIZE, BY TREATMENTS, 2018-2023 (USD MILLION)
TABLE 294. GERMANY ALPORT SYNDROME MARKET SIZE, BY TREATMENTS, 2024-2030 (USD MILLION)
TABLE 295. GERMANY ALPORT SYNDROME MARKET SIZE, BY GENETIC TYPE, 2018-2023 (USD MILLION)
TABLE 296. GERMANY ALPORT SYNDROME MARKET SIZE, BY GENETIC TYPE, 2024-2030 (USD MILLION)
TABLE 297. GERMANY ALPORT SYNDROME MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
TABLE 298. GERMANY ALPORT SYNDROME MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
TABLE 299. ISRAEL ALPORT SYNDROME MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
TABLE 300. ISRAEL ALPORT SYNDROME MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
TABLE 301. ISRAEL ALPORT SYNDROME MARKET SIZE, BY DIAGNOSIS, 2018-2023 (USD MILLION)
TABLE 302. ISRAEL ALPORT SYNDROME MARKET SIZE, BY DIAGNOSIS, 2024-2030 (USD MILLION)
TABLE 303. ISRAEL ALPORT SYNDROME MARKET SIZE, BY TREATMENTS, 2018-2023 (USD MILLION)
TABLE 304. ISRAEL ALPORT SYNDROME MARKET SIZE, BY TREATMENTS, 2024-2030 (USD MILLION)
TABLE 305. ISRAEL ALPORT SYNDROME MARKET SIZE, BY GENETIC TYPE, 2018-2023 (USD MILLION)
TABLE 306. ISRAEL ALPORT SYNDROME MARKET SIZE, BY GENETIC TYPE, 2024-2030 (USD MILLION)
TABLE 307. ISRAEL ALPORT SYNDROME MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
TABLE 308. ISRAEL ALPORT SYNDROME MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
TABLE 309. ITALY ALPORT SYNDROME MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
TABLE 310. ITALY ALPORT SYNDROME MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
TABLE 311. ITALY ALPORT SYNDROME MARKET SIZE, BY DIAGNOSIS, 2018-2023 (USD MILLION)
TABLE 312. ITALY ALPORT SYNDROME MARKET SIZE, BY DIAGNOSIS, 2024-2030 (USD MILLION)
TABLE 313. ITALY ALPORT SYNDROME MARKET SIZE, BY TREATMENTS, 2018-2023 (USD MILLION)
TABLE 314. ITALY ALPORT SYNDROME MARKET SIZE, BY TREATMENTS, 2024-2030 (USD MILLION)
TABLE 315. ITALY ALPORT SYNDROME MARKET SIZE, BY GENETIC TYPE, 2018-2023 (USD MILLION)
TABLE 316. ITALY ALPORT SYNDROME MARKET SIZE, BY GENETIC TYPE, 2024-2030 (USD MILLION)
TABLE 317. ITALY ALPORT SYNDROME MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
TABLE 318. ITALY ALPORT SYNDROME MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
TABLE 319. NETHERLANDS ALPORT SYNDROME MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
TABLE 320. NETHERLANDS ALPORT SYNDROME MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
TABLE 321. NETHERLANDS ALPORT SYNDROME MARKET SIZE, BY DIAGNOSIS, 2018-2023 (USD MILLION)
TABLE 322. NETHERLANDS ALPORT SYNDROME MARKET SIZE, BY DIAGNOSIS, 2024-2030 (USD MILLION)
TABLE 323. NETHERLANDS ALPORT SYNDROME MARKET SIZE, BY TREATMENTS, 2018-2023 (USD MILLION)
TABLE 324. NETHERLANDS ALPORT SYNDROME MARKET SIZE, BY TREATMENTS, 2024-2030 (USD MILLION)
TABLE 325. NETHERLANDS ALPORT SYNDROME MARKET SIZE, BY GENETIC TYPE, 2018-2023 (USD MILLION)
TABLE 326. NETHERLANDS ALPORT SYNDROME MARKET SIZE, BY GENETIC TYPE, 2024-2030 (USD MILLION)
TABLE 327. NETHERLANDS ALPORT SYNDROME MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
TABLE 328. NETHERLANDS ALPORT SYNDROME MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
TABLE 329. NIGERIA ALPORT SYNDROME MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
TABLE 330. NIGERIA ALPORT SYNDROME MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
TABLE 331. NIGERIA ALPORT SYNDROME MARKET SIZE, BY DIAGNOSIS, 2018-2023 (USD MILLION)
TABLE 332. NIGERIA ALPORT SYNDROME MARKET SIZE, BY DIAGNOSIS, 2024-2030 (USD MILLION)
TABLE 333. NIGERIA ALPORT SYNDROME MARKET SIZE, BY TREATMENTS, 2018-2023 (USD MILLION)
TABLE 334. NIGERIA ALPORT SYNDROME MARKET SIZE, BY TREATMENTS, 2024-2030 (USD MILLION)
TABLE 335. NIGERIA ALPORT SYNDROME MARKET SIZE, BY GENETIC TYPE, 2018-2023 (USD MILLION)
TABLE 336. NIGERIA ALPORT SYNDROME MARKET SIZE, BY GENETIC TYPE, 2024-2030 (USD MILLION)
TABLE 337. NIGERIA ALPORT SYNDROME MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
TABLE 338. NIGERIA ALPORT SYNDROME MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
TABLE 339. NORWAY ALPORT SYNDROME MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
TABLE 340. NORWAY ALPORT SYNDROME MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
TABLE 341. NORWAY ALPORT SYNDROME MARKET SIZE, BY DIAGNOSIS, 2018-2023 (USD MILLION)
TABLE 342. NORWAY ALPORT SYNDROME MARKET SIZE, BY DIAGNOSIS, 2024-2030 (USD MILLION)
TABLE 343. NORWAY ALPORT SYNDROME MARKET SIZE, BY TREATMENTS, 2018-2023 (USD MILLION)
TABLE 344. NORWAY ALPORT SYNDROME MARKET SIZE, BY TREATMENTS, 2024-2030 (USD MILLION)
TABLE 345. NORWAY ALPORT SYNDROME MARKET SIZE, BY GENETIC TYPE, 2018-2023 (USD MILLION)
TABLE 346. NORWAY ALPORT SYNDROME MARKET SIZE, BY GENETIC TYPE, 2024-2030 (USD MILLION)
TABLE 347. NORWAY ALPORT SYNDROME MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
TABLE 348. NORWAY ALPORT SYNDROME MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
TABLE 349. POLAND ALPORT SYNDROME MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
TABLE 350. POLAND ALPORT SYNDROME MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
TABLE 351. POLAND ALPORT SYNDROME MARKET SIZE, BY DIAGNOSIS, 2018-2023 (USD MILLION)
TABLE 352. POLAND ALPORT SYNDROME MARKET SIZE, BY DIAGNOSIS, 2024-2030 (USD MILLION)
TABLE 353. POLAND ALPORT SYNDROME MARKET SIZE, BY TREATMENTS, 2018-2023 (USD MILLION)
TABLE 354. POLAND ALPORT SYNDROME MARKET SIZE, BY TREATMENTS, 2024-2030 (USD MILLION)
TABLE 355. POLAND ALPORT SYNDROME MARKET SIZE, BY GENETIC TYPE, 2018-2023 (USD MILLION)
TABLE 356. POLAND ALPORT SYNDROME MARKET SIZE, BY GENETIC TYPE, 2024-2030 (USD MILLION)
TABLE 357. POLAND ALPORT SYNDROME MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
TABLE 358. POLAND ALPORT SYNDROME MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
TABLE 359. QATAR ALPORT SYNDROME MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
TABLE 360. QATAR ALPORT SYNDROME MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
TABLE 361. QATAR ALPORT SYNDROME MARKET SIZE, BY DIAGNOSIS, 2018-2023 (USD MILLION)
TABLE 362. QATAR ALPORT SYNDROME MARKET SIZE, BY DIAGNOSIS, 2024-2030 (USD MILLION)
TABLE 363. QATAR ALPORT SYNDROME MARKET SIZE, BY TREATMENTS, 2018-2023 (USD MILLION)
TABLE 364. QATAR ALPORT SYNDROME MARKET SIZE, BY TREATMENTS, 2024-2030 (USD MILLION)
TABLE 365. QATAR ALPORT SYNDROME MARKET SIZE, BY GENETIC TYPE, 2018-2023 (USD MILLION)
TABLE 366. QATAR ALPORT SYNDROME MARKET SIZE, BY GENETIC TYPE, 2024-2030 (USD MILLION)
TABLE 367. QATAR ALPORT SYNDROME MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
TABLE 368. QATAR ALPORT SYNDROME MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
TABLE 369. RUSSIA ALPORT SYNDROME MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
TABLE 370. RUSSIA ALPORT SYNDROME MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
TABLE 371. RUSSIA ALPORT SYNDROME MARKET SIZE, BY DIAGNOSIS, 2018-2023 (USD MILLION)
TABLE 372. RUSSIA ALPORT SYNDROME MARKET SIZE, BY DIAGNOSIS, 2024-2030 (USD MILLION)
TABLE 373. RUSSIA ALPORT SYNDROME MARKET SIZE, BY TREATMENTS, 2018-2023 (USD MILLION)
TABLE 374. RUSSIA ALPORT SYNDROME MARKET SIZE, BY TREA